Contattaci
Circa la società
The pharmaceutical companies are eager to obtain maximum information from fewer clinical trials at early stage. This enables quicker “go/no-go” decision for the development strategy of a given compound. The landscape of early clinical development has dramatically changed over the last years. The amount of Phase 1 studies in healthy volunteers has decreased, being replaced by Phase 1b/2a studies in patients.
DE
Sconosciuto
Sconosciuto
Azienda non verificata
Trasparenza aziendale
- Informazioni sull'azienda non verificate
- Chiedi ai loro clienti per le recensioni
- Non ha risposto alle recensioni negative